Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone

Zhongshan Hospital, Fudan University

This study is to examine whether radical prostatectomy can impact survival and quality-of-life in men with oligo-metastatic prostate cancer.

In this study, patients with oligo-metastatic prostate cancer will be randomized to radical prostatectomy plus standard care and standard care only. Standard care refers to androgen deprivation therapy (ADT) +/- other systemic therapies. Time to disease progression and post-treatment quality of life will be assessed and compared.

Inclusion Criteria:

• Participants is willing and able to give informed consent for participation in the study
• Male aged 19-75 years.
• Diagnosed with oligo-metastatic prostate cancer (1-3 skeletal lesions on bone specific imaging, no visceral metastases).
• Locally resectable tumor (clinical/radiological stage T1-T3).
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Suitable for radical prostatectomy within 12 months of starting standard care.

Exclusion Criteria:

• Contraindications to radical prostatectomy.
• Visceral metastases.
• Prior radiotherapy to the abdomen/pelvis or to skeletal metastases.
• Any systemic therapy of prostate cancer (including standard care) for 12 or more months prior to enrollment.
• Current involvement in other interventional research.